文章核心观点 - 能长期存续且发展良好的公司通常具备创新能力、行业领导地位、强大护城河或高增长潜力等特征 以微软和雅培实验室为例，它们不仅前景好，还是优秀的股息支付公司，值得长期持有 [1] 微软相关要点 - 微软知名度高，品牌广为人知且消费者信任度较高 [2] - 微软在计算机操作系统市场份额领先，其生产力工具被广泛使用，带来高转换成本 [2] - 微软操作系统业务增长放缓，但在云计算和人工智能领域有发展机会，在云市场仅次于亚马逊 [2] - 人工智能推动微软云业务发展，公司在各业务领域均处于领先地位，创新能力强 [3] - 微软自由现金流达705.8亿美元，财务表现好，有能力投资更多增长机会 [4] - 微软获标准普尔AAA评级，高于美国政府 [4] - 微软股息收益率为0.66%，过去10年股息支付增长168%，现金派息率30.11%，有提升空间 [4] - 微软适合股息投资者和寻求可靠投资标的的投资者 [5] 雅培实验室相关要点 - 雅培实验室在开发创新医疗技术方面表现出色，产品丰富，涵盖心血管和糖尿病护理等领域 [6] - 雅培实验室的FreeStyle Libre系列连续血糖监测系统是近年最大增长驱动力，是史上销售额最高的医疗设备 [6] - 雅培实验室业务多元化，包括营养、诊断和成熟制药等领域，拥有专利保护产品 [6][7] - 雅培实验室长期在高度监管的医疗行业运营，积累经验且品牌受信任 [7] - 随着全球人口老龄化和糖尿病市场渗透率低等因素，雅培实验室仍有获得高回报的机会 [7] - 雅培实验室连续52年增加股息支付，能长期维持高回报和股息增长 [8]

Loading...Loading...Abbott Laboratories ABT is scheduled to release its financial results for the second quarter, before the opening bell on Thursday, July 18.Analysts expect the North Chicago, Illinois-based company to report quarterly earnings at $1.10 per share, up from $1.08 per share in the year-ago period. Abbott expects to post revenue of $10.37 billion. It posted $9.7 billion a year earlier, according to data from Benzinga Pro.On June 14, Abbott declared a quarterly common dividend of 55 cents per s ...

LAS VEGAS, NEVADA - JANUARY 10: An Abbott logo is displayed at the company's booth during CES 2024 ... [+] at the Las Vegas Convention Center on January 10, 2024 in Las Vegas, Nevada. (Photo by Ethan Miller/Getty Images)Getty ImagesAbbott (NYSE: ABT) will report its Q2 2024 results on Thursday, July 18. We expect the company to post revenue of $10.3 billion and earnings of $1.10 on a per share and adjusted basis, broadly aligning with the street expectations. We expect a low single-digit uptick in sales for ...

Over the years, especially the past three, I have become more cautious about the technology sector’s blatant overvaluation. Nevertheless, it is difficult to ignore the capabilities of companies such as Nvidia (NASDAQ:NVDA) and their innovative solutions for AI. Although, in my opinion, the market’s optimism has still led to high valuations. This is why I am shifting my focus to undervalued healthcare stocks as a means of protecting myself from the overvaluation of the technology sector.I think that the heal ...

Abbott Laboratories (ABT) is slated to report its second-quarter 2024 results on Jul 18, before the opening bell.The company posted adjusted earnings per share (EPS) of 98 cents in the last quarter, which topped the Zacks Consensus Estimate by 2.08%. In the trailing four quarters, its earnings exceeded the Zacks Consensus Estimate on all four occasions, the average beat being 2.39%.Q2 EstimatesThe Zacks Consensus Estimate for ABT’s second-quarter 2024 revenues is pegged at $10.35 billion. This suggests a 3. ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Abbott (ABT) .Abbott currently has an average brokerage recommendation (AB ...

In my view, it’s important for every individual to invest in equities. By just holding cash in a back account, there is bound to be loss of purchasing power when adjusted for inflation. To maintain or increase purchasing power, investors need exposure to risky asset classes.However, not all investors have the appetite for high-risk that’s associated with growth or penny stocks. The remedy is to invest in low-beta stocks that deliver steady returns and protect the portfolio from extreme volatility. The focus ...

公司表现 - 公司最新交易日收盘价为$101.64，较前一交易日下跌0.47%，表现落后于S&P 500指数的0.07%涨幅，同时道琼斯指数下跌0.13%，纳斯达克指数上涨0.14% [1] - 公司股价在过去一个月内下跌了5%，未能跟上医疗行业1.99%的跌幅和S&P 500指数4.34%的涨幅 [1] - 公司预计将于2024年7月18日发布财报，预计每股收益(EPS)为$1.10，同比增长1.85%，营收预计为$10.35 billion，同比增长3.78% [1] - 全年预计每股收益为$4.62，营收为$41.66 billion，分别同比增长4.05%和3.86% [2] 分析师估计与估值 - 公司目前的Zacks Rank为3 (Hold)，过去30天内Zacks Consensus EPS估计保持不变 [3] - 公司当前的Forward P/E比率为22.11，高于其行业平均的21.87 [3] - 公司的PEG比率为2.46，高于医疗产品行业平均的2.24 [3] 行业分析 - 医疗产品行业属于医疗行业，目前Zacks Industry Rank为166，位于所有250+行业的底部35% [4] - Zacks Industry Rank通过衡量行业内个股的平均Zacks Rank来评估行业实力，研究表明，排名前50%的行业表现优于后50%的行业，比例为2:1 [4]

undefined/iStock via Getty Images 2024 Review A positive trajectory resumed for the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) during the month of May. The ETF posted a modest gain of 1.45% during the month. Albeit some of this optimism has faded in June with the ETF sitting in the red near the end of the month. Year-to-date, through June 26th NOBL is up 2.44%. Several dividend aristocrats are running at a much faster pace than NOBL in 2024. Let's take a look at which individual aristocrats are drivi ...

Fundamentally, few sectors exist outside of the broad healthcare umbrella that offer what I would term permanent relevance. In this case, the concept of caring for other people is likely an eternal one. So, it makes sense to consider medical technology or MedTech stocks to buy.As you know, the innovation ecosystem constantly moves in one direction: forward. It seems like every day, someone is talking about artificial intelligence or automated robotics or some invention in the connectivity arena. Enterprises ...